Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib
Background/Aims: The use of tyrosine kinase inhibitors (TKIs) to target active epidermal growth factor receptor (EGFR)-harbouring mutations has been effective in patients with advanced non-small-cell lung cancer (NSCLC). However, the use of TKIs in NSCLS patients with somatic EGFR mutations, particu...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cell Physiol Biochem Press GmbH & Co KG
2014-08-01
|
| Series: | Cellular Physiology and Biochemistry |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/366305 |
| _version_ | 1818508743434829824 |
|---|---|
| author | Miyong Yun Eun-Ok Kim Duckgue Lee Ji-Hyun Kim Jaekwang Kim Hyemin Lee Jihyun Lee Sung-Hoon Kim |
| author_facet | Miyong Yun Eun-Ok Kim Duckgue Lee Ji-Hyun Kim Jaekwang Kim Hyemin Lee Jihyun Lee Sung-Hoon Kim |
| author_sort | Miyong Yun |
| collection | DOAJ |
| description | Background/Aims: The use of tyrosine kinase inhibitors (TKIs) to target active epidermal growth factor receptor (EGFR)-harbouring mutations has been effective in patients with advanced non-small-cell lung cancer (NSCLC). However, the use of TKIs in NSCLS patients with somatic EGFR mutations, particularly T790M, causes drug resistance. Thus, in the present study, we investigated overcoming resistance against the TKI gefitinib by combination treatment with melatonin in H1975 NSCLC cells harbouring the T790M somatic mutation. Methods: H1975 and HCC827 cells were treated with melatonin in combination with gefitinib, and cell viability, cell cycle progression, apoptosis, and EGFR, AKT, p38, Bcl-2, Bcl-xL, caspase 3 and Bad protein levels were examined. Results: Treatment with melatonin dose-dependently decreased the viability of H1975 cells harbouring the T790M somatic mutation compared to HCC827 cells with an EGFR active mutation. Melatonin-mediated cell death resulted in decreased phosphorylation of EGFR and Akt, leading to attenuated expression of survival proteins, such as Bcl-2, Bcl-xL and survivin, and activated caspase 3 in H1975 cells, but not in HCC827 cells. However, we did not observe a significant change in expression of cell cycle proteins, such as cyclin D, cyclin A, p21 and CDK4 in H1975 cells. Surprisingly, co-treatment of gefitinib with melatonin effectively decreased the viability of H1975 cells, but not HCC827 cells. Moreover, co-treatment of H1975 cells caused consistent down-regulation of EGFR phosphorylation and induced apoptosis compared to treatment with gefitinib or melatonin alone. Conclusions: Our findings demonstrate that melatonin acts as a potent chemotherapeutic agent by sensitising to gefitinib TKI-resistant H1975 cells that harbour a EGFR T790M mutation. |
| first_indexed | 2024-12-10T22:36:09Z |
| format | Article |
| id | doaj.art-729ff952e9de4d8e94c38d813c652bf4 |
| institution | Directory Open Access Journal |
| issn | 1015-8987 1421-9778 |
| language | English |
| last_indexed | 2024-12-10T22:36:09Z |
| publishDate | 2014-08-01 |
| publisher | Cell Physiol Biochem Press GmbH & Co KG |
| record_format | Article |
| series | Cellular Physiology and Biochemistry |
| spelling | doaj.art-729ff952e9de4d8e94c38d813c652bf42022-12-22T01:30:53ZengCell Physiol Biochem Press GmbH & Co KGCellular Physiology and Biochemistry1015-89871421-97782014-08-0134386587210.1159/000366305366305Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor GefitinibMiyong YunEun-Ok KimDuckgue LeeJi-Hyun KimJaekwang KimHyemin LeeJihyun LeeSung-Hoon KimBackground/Aims: The use of tyrosine kinase inhibitors (TKIs) to target active epidermal growth factor receptor (EGFR)-harbouring mutations has been effective in patients with advanced non-small-cell lung cancer (NSCLC). However, the use of TKIs in NSCLS patients with somatic EGFR mutations, particularly T790M, causes drug resistance. Thus, in the present study, we investigated overcoming resistance against the TKI gefitinib by combination treatment with melatonin in H1975 NSCLC cells harbouring the T790M somatic mutation. Methods: H1975 and HCC827 cells were treated with melatonin in combination with gefitinib, and cell viability, cell cycle progression, apoptosis, and EGFR, AKT, p38, Bcl-2, Bcl-xL, caspase 3 and Bad protein levels were examined. Results: Treatment with melatonin dose-dependently decreased the viability of H1975 cells harbouring the T790M somatic mutation compared to HCC827 cells with an EGFR active mutation. Melatonin-mediated cell death resulted in decreased phosphorylation of EGFR and Akt, leading to attenuated expression of survival proteins, such as Bcl-2, Bcl-xL and survivin, and activated caspase 3 in H1975 cells, but not in HCC827 cells. However, we did not observe a significant change in expression of cell cycle proteins, such as cyclin D, cyclin A, p21 and CDK4 in H1975 cells. Surprisingly, co-treatment of gefitinib with melatonin effectively decreased the viability of H1975 cells, but not HCC827 cells. Moreover, co-treatment of H1975 cells caused consistent down-regulation of EGFR phosphorylation and induced apoptosis compared to treatment with gefitinib or melatonin alone. Conclusions: Our findings demonstrate that melatonin acts as a potent chemotherapeutic agent by sensitising to gefitinib TKI-resistant H1975 cells that harbour a EGFR T790M mutation.http://www.karger.com/Article/FullText/366305MelatoninH1975HCC827EGFRBcl-2AKTBad |
| spellingShingle | Miyong Yun Eun-Ok Kim Duckgue Lee Ji-Hyun Kim Jaekwang Kim Hyemin Lee Jihyun Lee Sung-Hoon Kim Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib Cellular Physiology and Biochemistry Melatonin H1975 HCC827 EGFR Bcl-2 AKT Bad |
| title | Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib |
| title_full | Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib |
| title_fullStr | Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib |
| title_full_unstemmed | Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib |
| title_short | Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib |
| title_sort | melatonin sensitizes h1975 non small cell lung cancer cells harboring a t790m targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib |
| topic | Melatonin H1975 HCC827 EGFR Bcl-2 AKT Bad |
| url | http://www.karger.com/Article/FullText/366305 |
| work_keys_str_mv | AT miyongyun melatoninsensitizesh1975nonsmallcelllungcancercellsharboringat790mtargetedepidermalgrowthfactorreceptormutationtothetyrosinekinaseinhibitorgefitinib AT eunokkim melatoninsensitizesh1975nonsmallcelllungcancercellsharboringat790mtargetedepidermalgrowthfactorreceptormutationtothetyrosinekinaseinhibitorgefitinib AT duckguelee melatoninsensitizesh1975nonsmallcelllungcancercellsharboringat790mtargetedepidermalgrowthfactorreceptormutationtothetyrosinekinaseinhibitorgefitinib AT jihyunkim melatoninsensitizesh1975nonsmallcelllungcancercellsharboringat790mtargetedepidermalgrowthfactorreceptormutationtothetyrosinekinaseinhibitorgefitinib AT jaekwangkim melatoninsensitizesh1975nonsmallcelllungcancercellsharboringat790mtargetedepidermalgrowthfactorreceptormutationtothetyrosinekinaseinhibitorgefitinib AT hyeminlee melatoninsensitizesh1975nonsmallcelllungcancercellsharboringat790mtargetedepidermalgrowthfactorreceptormutationtothetyrosinekinaseinhibitorgefitinib AT jihyunlee melatoninsensitizesh1975nonsmallcelllungcancercellsharboringat790mtargetedepidermalgrowthfactorreceptormutationtothetyrosinekinaseinhibitorgefitinib AT sunghoonkim melatoninsensitizesh1975nonsmallcelllungcancercellsharboringat790mtargetedepidermalgrowthfactorreceptormutationtothetyrosinekinaseinhibitorgefitinib |